01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#VELA investee co. #ENSI Ensilica PLC – EnSilica joins TSMC Design Center Alliance September 19, 2024 – Posted in: Vela Technologies Plc (VELA)

EnSilica, a leading chip maker of mixed signal ASICs (Application Specific Integrated Circuits), is pleased to announce that it has joined the Design Center Alliance (“DCA”) of the Taiwan Semiconductor Manufacturing Company’s (“TSMC”) Open Innovation Platform® (“OIP”). TSMC’s DCA programme focuses on chip implementation service and system level design solution enablement to lower the design barriers for customers adopting TSMC technology. EnSilica’s partnership with TSMC through the DCA programme strengthens EnSilica’s value in enabling the…

Continue reading

#HVO hVIVO plc- Share Price November 11, 2022 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, saw the share price rise which was then picked up in the Daily Mail Stock Watch this morning   For further information please contact:   hVIVO plc +44 (0) 20 7756 1300 Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer Liberum…

Continue reading

#HVO hVIVO PLC- £13.6m RSV antiviral contract November 10, 2022 – Posted in: Open Orphan (ORPH)

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £13.6m contract with a US-based biopharmaceutical client to test its respiratory syncytial virus (“RSV”) antiviral candidate, using hVIVO’s established RSV Human Challenge Study Model                                 The Phase 2a double-blinded placebo-controlled human challenge trial will take place at…

Continue reading